Form 4: 4D Molecular Therapeutics VP Finance Sells Shares for Tax

Ashoo Gupta, VP of Finance and Controller at 4D Molecular Therapeutics, reported the conversion of Restricted Stock Units into common stock and subsequent sales to cover tax obligations.

Summary

• Ashoo Gupta, VP, Finance and Controller of 4D Molecular Therapeutics, Inc. (FDMT), reported transactions on December 20, 2025.
• Gupta acquired a total of 1,086 shares of common stock through the conversion of Restricted Stock Units (RSUs) on a one-for-one basis.
• Concurrently, Gupta disposed of 389 shares of common stock at a price of $8.68 per share.
• These sales were automatic "sell to cover" transactions, specifically to satisfy tax withholding obligations, and were not discretionary trades.
• Following these transactions, Gupta's direct beneficial ownership of common stock is 46,359 shares.
• Gupta also beneficially owns 16,292 Restricted Stock Units (RSUs) which will vest according to pre-determined schedules.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving RSU vesting and subsequent 'sell to cover' sales for tax purposes. These are expected events and do not indicate a discretionary change in the executive's confidence or the company's prospects. The continued significant beneficial ownership is a neutral to slightly positive signal.

Positives

• Vesting of 1,086 Restricted Stock Units (RSUs) into common stock, increasing direct ownership before tax sales.
• Continued significant beneficial ownership of 46,359 common shares and 16,292 RSUs by a key executive.

Negatives

• Disposal of 389 shares of common stock, reducing the executive's direct shareholding, even if for tax purposes.

Future Outlook

The filing indicates future vesting of Restricted Stock Units (RSUs) for Ashoo Gupta, with portions vesting quarterly after June 20, 2025, as long as the grantee remains a service provider to the company.

Industry Context

This Form 4 filing reflects routine insider compensation and tax-related transactions common across publicly traded companies, particularly in the biotechnology sector where equity compensation like RSUs is a standard component of executive pay.

Related Party Transactions

• Conversion of Restricted Stock Units (RSUs) into common stock for Ashoo Gupta, an officer of the company, as part of an equity compensation plan.
• Automatic "sell to cover" transactions of common stock by Ashoo Gupta to satisfy tax withholding obligations arising from the RSU vesting.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion (already accounted for in outstanding shares), but the "sell to cover" is not a discretionary sale, so it typically has minimal impact on investor sentiment.
• Employees: Reinforces the company's equity compensation structure for executives.

Next Steps

• Continued quarterly vesting of remaining Restricted Stock Units (RSUs) for Ashoo Gupta, contingent on continued service to the company.

Key Dates

Recommendation

This Form 4 filing details routine, non-discretionary transactions by an insider related to the vesting of Restricted Stock Units and subsequent sales to cover tax obligations. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information that would warrant a change from a 'hold' recommendation.

Keywords

4D Molecular Therapeutics, FDMT, Ashoo Gupta, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Sell to Cover, Tax Withholding, Beneficial Ownership